Loading
A phase 2 trial of HLX43 DOSE 1 (2.0 mg/kg) in non-small-cell lung cancer, run by Shanghai Henlius Biotech, now recruiting.
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06907615 by Shanghai Henlius Biotech, with 243 participants planned, started 2025-06-09 and due to reach its primary completion in 2028-04-20. Interventions recorded: HLX43 DOSE 1 (2.0 mg/kg) and HLX43 DOSE 2 (2.5 mg/kg).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Henlius Biotech and the tag pipeline.
Shares Shanghai Henlius Biotech, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/